옵션 체인은 다양한 행사가격과 만기일에 대한 Processa Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Processa Pharmaceuticals에 대한 시장 심리를 평가합니다..

Processa Pharmaceuticals (NASDAQ:PCSA) 주식, 옵션 체인

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Constellation Brands

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ANGO

BIGC

LEVI

PCSA

목요일 아침 (현지 시간 기준) 미국 주식 선물이 하락세를 보이면서 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 컨스텔레이션 브랜드(NYSE:STZ)가 분기 이익을 주당 4.08달러, 매출 29억 달러로 발표할 것으로 예상하고 있다. 컨스텔레이션 주식은 애프터 마켓에서 0.3% 하락한 254.90달러로 거래되고 있다.

목요일 주목해야 할 주식: 컨스텔레이션 브랜드, 리바이 스트라우스 그리고 3종목

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

Baird analyst Craig Kennison maintains Patrick Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) with a Neutral and lowers the price target from $96 to $84.

Price Target

Analyst Ratings

PATK

Baird Maintains Neutral on Patrick Industries, Lowers Price Target to $84

Baird analyst Craig Kennison maintains OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) with a Neutral and lowers the price target from $18 to $17.

ONEW

Baird Maintains Neutral on OneWater Marine, Lowers Price Target to $17

Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Buy and maintains $29 price target.

Reiteration

BCYC

Needham Reiterates Buy on Bicycle Therapeutics, Maintains $29 Price Target

Baird analyst David Tarantino maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Neutral and raises the price target from $300 to $315.

Baird Maintains Neutral on McDonald's, Raises Price Target to $315

Rosenblatt analyst Barton Crockett maintains Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) with a Neutral and lowers the price target from $24 to $22.

SIRI

Rosenblatt Maintains Neutral on Sirius XM Holdings, Lowers Price Target to $22

Baird analyst Mark Altschwager maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Neutral and lowers the price target from $9 to $8.

Baird Maintains Neutral on Kohl's, Lowers Price Target to $8

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Hold to Hold.

BIIB

Needham Reiterates Hold on Biogento Hold

As the U.S. Army approaches its 250th anniversary, the Secretary of Defense Pete Hegseth issued a directive earlier this week outlining an ambitious roadmap to reshape the Army's structure, workforce, and acquisition systems. It also aims to equip each of its 10 combat divisions with around 1,000 drones.
What Happened: Framed around President Donald Trump's "Peace through Strength" doctrine, the strategy calls for the divestment of outdated armor and aviation formations across all Army components, <a href="https://www.wsj.com/politics/national-security/us-army-drones-shift-20cc5753'">reported</a> The Wall Street Journal.
It mandates the consolidation or closure of redundant headquarters. The plan also restructures sustainment commands, reviews underused depots, and seeks commercial leasing partnerships to boost the defense industrial base.
On the personnel front, the Army will revise civilian hiring and firing policies, reduce general officer positions, and streamline command structures.
Acquisition reforms include shifting to capability-based <a href="https://www.benzinga.com/news/25/02/43980072/theres-no-reason-to-spend-1-trillion-on-the-military-trumps-statement-sends-us-defense-stocks-spiraling-whil">budgeting</a>, enabling the right to repair, and expanding rapid prototyping contracts for <a href="https://www.benzinga.com/news/contracts/25/04/44717132/teledyne-secures-74-2m-us-army-contract-to-enhance-sensor-tech">emerging technologies</a>.
See Also: <a href="https://www.benzinga.com/25/04/44655959/elon-musks-spacex-jeff-bezos-blue-origin-and-boeing-lockheeds-ula-bag-13-5-billion-pentagon-launch-contracts">Elon Musk&#8217;s SpaceX, Jeff Bezos&#8217; Blue Origin, And Boeing-Lockheed&#8217;s ULA Bag $13.5 Billion Pentagon Launch Contracts</a>
Why it matters: The changes follow over a year of testing at training grounds like Hohenfels, Germany and include debriefings with Ukrainian military personnel and contractors. The drones will be used for surveillance, supply transport, and attacks. The broader $36 billion plan also includes retiring outdated systems, enhancing electronic warfare capabilities, and improving battlefield connectivity.
These efforts are designed to counter rising <a href="https://www.benzinga.com/markets/25/04/44866615/russia-uses-seized-american-company-to-supply-food-to-russian-army-report">threats from Russia</a> and China, and mark the army's most significant overhaul since the Cold War.
Read Next: <a href="https://www.benzinga.com/markets/25/04/44776673/pentagon-slashes-5-1-billion-in-accenture-deloitte-booz-allen-contracts-thats-a-lot-of-consulting">Pentagon Slashes $5.1 Billion In Accenture, Deloitte, Booz Allen Contracts: &#8216;That&#8217;s A Lot Of Consulting&#8217;</a>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock/Jeremy Christensen

Politics

Global

Pentagon Unveils $36 Billion Army Overhaul With 1,000 Drones Per Division To Counter Rising Threats From China And Russia

Rosenblatt analyst Mike Genovese maintains Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) with a Buy and raises the price target from $12 to $13.5.

VIAV

Rosenblatt Maintains Buy on Viavi Solutions, Raises Price Target to $13.5

Maris-Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEK#NASDAQ">MTEK</a>, MTEKW))) ("Maris-Tech" or the "Company"), a global leader in video and artificial intelligence ("AI")- based edge computing technology, today announced that it has entered into a new distribution agreement with Armit Sp. z o.o. ("Armit"), a leading Polish defense solutions provider. The collaboration represents a key step in Maris-Tech's European growth strategy, which is to expand access to its advanced video streaming, AI, and situational awareness platforms in one of Europe's most strategically important defense markets.

MTEK

Maris-Tech Enters Into New Distribution Agreement With Armit To Address Growing Demand For Defense Video & AI Solutions

A new report on sentiment in the crypto sector indicates that the market recovery has not had an equal impact on all cryptocurrencies, but retail excitement is rising and <a href="https://www.benzinga.com/money/bitcoin-price-prediction">risk appetite growing.</a>
What Happened: In a detailed <a href="https://x.com/santimentfeed/status/1918053170204570045">post</a> on X on May 2, on-chain analytics provider Santiment shared how Bitcoin's rebound to the $94,000–$96,000 range has reignited market-wide enthusiasm. 
Total crypto market capitalization has jumped 10% in the final eight days of April, driven by retail momentum.
However, Bitcoin's modest 7% gain over that period suggests capital is rotating into altcoins and meme coins, a classic risk-on signal often seen during the late stages of crypto rallies. 
This pattern echoes post-FTX recoveries, where Bitcoin leads early, then stalls as traders chase bigger gains in speculative names.
Santiment warns that while ETF narratives may prolong the rally, sentiment-fueled surges often reverse sharply. 
"Greed-driven markets can create several short-term gains to test your resolve in profit taking," the report cautioned, highlighting overconfidence can quickly become a liability.
As the market enters May, the key question is whether altcoins can sustain the momentum or if this is just another hype-driven spike destined to fade.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45076518/bitcoin-is-a-commodity-like-gold-says-commerce-secretary-lutnick">Bitcoin Is A Commodity Like Gold, Says Commerce Secretary Lutnick</a>
Why It Matters: Santiment points to key asset narratives highlighting the crypto market's changing sentiments towards them.
<ul>
<li>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>): It has rebounded sharply after early-April bearish sentiment, flipping social sentiment from fear to renewed fear of missing out. Now making up 25% of crypto discussions, with more positive commentary than negative.</li>
<li>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>): While lagging in price and attention, sentiment is turning bullish, aided by KOL support and renewed commentary from Vitalik Buterin. ETH's social dominance remains low (6–7%), down from historical norms near 10%.</li>
<li>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>): Traders are increasingly bullish due to rising odds (85%) of an XRP spot ETF approval. Despite a price dip, optimism remains strong, fueled by institutional interest and ETF expectations. Grayscale and Bitwise have lined up to launch XRP-based funds attracting significant interest in the altcoin.</li>
<li>BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>): After strong gains in Feb–Mar due to Binance's support and Trump-related rumors, excitement has waned. Social buzz is down, but a new Trump–CZ partnership could revive attention.</li>
<li>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>): Underperformed in price and interest over the last three months. Despite brief spikes, possibly amplified by bots, overall attention is fading. Still, talk of a SOL ETF and bullish market positioning keep it in the spotlight. The asset is currently taking up about 4.4% of all crypto discussions but was hovering at between 6–7% back in January and February.</li>
<li>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>): ETF filings from 21Shares and Bitwise have significantly boosted sentiment and legitimacy. Nasdaq filed a key document with the SEC to list the 21Shares Dogecoin ETF, marking an important step in mainstream adoption. Social dominance hit a 3-month high, with whale accumulation and bullish momentum building.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45112881/sell-bitcoin-ethereum-xrp-in-may-and-go-away-dont-be-so-sure-in-2025-expert-says">Sell Bitcoin, Ethereum, XRP In May And Go Away? Don&#8217;t Be So Sure In 2025, Expert Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$DOGE

$ETH

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Sentiment Rebounds As BTC Hits $97,000

Rosenblatt analyst Barton Crockett maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Neutral and lowers the price target from $100 to $75.

ROKU

Rosenblatt Maintains Neutral on Roku, Lowers Price Target to $75

As of May 2, 2025, three stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">QuinStreet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>)</h3>
<ul>
<li>QuinStreet will report financial results for its third quarter after the market closes on Wednesday, May 7. The company's stock jumped around 8% over the past five days and has a 52-week high of $26.27.</li>
<li>RSI Value: 70.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>QNST Price Action: Shares of QuinStreet jumped 6.8% to close at $18.71 on Thursday.</li>
<li>Edge Stock Ratings: 42.13 Momentum score with Value at 46.15. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/qnst"><img loading="lazy" decoding="async" width="483" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02042108/image-2-8.png" alt="" class="wp-image-898542" style="width:327px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02042108/image-2-8.png 483w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02042108/image-2-8-300x110.png 300w" sizes="(max-width: 483px) 100vw, 483px" /></a></figure>
<h3 class="wp-block-heading">Emerald Holding Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>)</h3>
<ul>
<li>On May 1, Emerald Holding reported better-than-expected first-quarter financial results and issued FY25 sales guidance with its midpoint above estimates. Hervé Sedky, Emerald&#8217;s President and Chief Executive Officer, said, &#8220;Our strong first-quarter performance underscores the meaningful progress we&#8217;ve made in executing our strategy and delivering value to both our customers and shareholders.&#8221; The company's stock gained around 18% over the past five days and <a href="https://www.benzinga.com/quote/EEX">has a 52-week high</a> of $6.74.</li>
<li>RSI Value: 78</li>
<li>EEX Price Action: Shares of Emerald Holding gained 15% to close at $4.52 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">HUYA Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUYA#NYSE">HUYA</a>)</h3>
<ul>
<li>HUYA will report its first quarter unaudited financial results on Tuesday, May 13, before the opening bell. The company's stock gained around 15% over the past month and has a<a href="https://www.benzinga.com/quote/HUYA"> 52-week high</a> of $6.84.</li>
<li>RSI Value: 70.3</li>
<li>HUYA Price Action: Shares of HUYA gained 1.6% to close at $3.82 on Thursday.</li>
</ul>
Don't miss out on the full BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">compare all the key stocks now</a>. 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

HUYA

QNST

Top 3 Tech And Telecom Stocks That May Crash In Q2

Rosenblatt analyst Catharine Trebnick maintains OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) with a Buy and maintains $20 price target.

OSPN

Rosenblatt Maintains Buy on OneSpan, Maintains $20 Price Target

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) reported stronger-than-expected first-quarter financial results <a href="https://www.benzinga.com/quote/AMZN/earnings">after market close Thursday.</a>
Amazon.com reported first-quarter net sales of $155.7 billion, up 9% year-over-year. The net sales beat a Street consensus estimate of $155.04 billion according to data from Benzinga Pro. The company reported first-quarter earnings per share of $1.59, beating a Street consensus estimate of $1.36.
&#8220;We&#8217;re pleased with the start to 2025, especially our pace of innovation and progress in continuing to improve customer experiences,&#8221; Amazon CEO Andy Jassy said.
The company said it expects second-quarter net sales of $159 billion to $164 billion, up 7% to 11%. Analysts expect the company to have net sales of $160.91 billion in the quarter.
Amazon shares gained 3.1% to close at $190.20 on Thursday.
These analysts made changes to their price targets on Amazon following earnings announcement.
<ul>
<li>Rosenblatt analyst Barton Crockett maintained Amazon.com with a Buy and raised the price target from $287 to $288.</li>
<li>JP Morgan analyst Doug Anmuth maintained the stock with an Overweight rating and raised the price target from $220 to $225.</li>
<li>Needham analyst Laura Martin, meanwhile, reiterated Amazon.com with a Buy and maintained a $220 price target.</li>
</ul>
Considering buying AMZN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="598" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02081120/image-24-1024x598.png" alt="" class="wp-image-898998" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02081120/image-24-1024x598.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02081120/image-24-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02081120/image-24-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02081120/image-24.png 1082w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

AMZN

These Analysts Boost Their Forecasts On Amazon Following Upbeat Q1 Results

Rosenblatt analyst Barton Crockett maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and lowers the price target from $174 to $170.

Rosenblatt Maintains Buy on Live Nation Entertainment, Lowers Price Target to $170

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $36 price target.

FIVN

Rosenblatt Maintains Buy on Five9, Maintains $36 Price Target

<h3>Gainers</h3>
<ul>
<li>Society Pass (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) stock rose 13.6% to $1.34 during Friday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) shares moved upwards by 8.43% to $0.59. The company's market cap stands at $6.3 million. </li>
<li>Integral Ad Science Holdi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAS#NASDAQ">IAS</a>) shares increased by 7.45% to $7.64. The market value of their outstanding shares is at $1.2 billion. </li>
<li>FingerMotion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNGR#NASDAQ">FNGR</a>) shares moved upwards by 7.14% to $2.55. The market value of their outstanding shares is at $145.7 million. </li>
<li>TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) stock increased by 6.78% to $0.31. The company's market cap stands at $13.6 million. </li>
<li>Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares rose 6.5% to $126.51. The company's market cap stands at $23.3 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) shares declined by 18.9% to $1.07 during Friday's pre-market session. The company's market cap stands at $346.0 million. </li>
<li>Emerald Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) stock decreased by 13.72% to $3.9. The market value of their outstanding shares is at $778.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares decreased by 13.27% to $28.99. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q1 earnings came out today. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) stock fell 13.16% to $0.33. The market value of their outstanding shares is at $8.6 million. As per the news, the FY earnings report came out yesterday. </li>
<li>Cable One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) shares fell 12.6% to $228.98. The company's market cap stands at $1.2 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) shares decreased by 9.84% to $212.05. The market value of their outstanding shares is at $37.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CABO

CRTO

FNGR

RDDT

SOPA

TNMG

TRUG

TTWO

12 Communication Services Stocks Moving In Friday's Pre-Market Session

The global copper market could experience a notable surplus over the next two years, as analysts anticipate rising production and weakening demand owing to<a target="_blank" href="https://www.benzinga.com/topic/trade-war" rel="noreferrer noopener"> rising international trade tensions</a>.
The International Copper Study Group (ICSG) concluded its biannual meeting in Lisbon this week, revising the projections. It now expects a <a target="_blank" href="https://icsg.org/press-releases/#" rel="noreferrer noopener">surplus of 289,000 metric tons</a> in 2025, more than double the 138,000 surplus in 2024. For 2026, it forecasts a smaller but elevated surplus of 209,000 tons owing to concerns over the economic fallout from U.S. tariffs and reduced copper usage in key global markets.
ICSG attributes the widening surplus primarily to increasing mine and smelter output. Global copper mine production is forecast to grow by 2.3% next year to 23.5 million tons, with major contributions from the ramp-up of the Ivanhoe's (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/IVPAF#OTCQX">IVPAF</a>) Kamoa-Kakula Complex in the Democratic Republic of Congo (DRC), Rio Tinto's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) Oyu Tolgoi in Mongolia, and the new Malmyz project in Russia.
In 2026, ICSG expects mine supply to grow by a further 2.5%, bolstered by new or expanded capacity in China, Chile, and Zambia and a recovery in Indonesian output. A wave of smaller operations in countries like Iran, Brazil, Eritrea, Greece, and Angola will also contribute.
The Group anticipates refined copper output will increase by 2.9% in 2025, driven by smelting expansions in China and new capacity in India, Indonesia, and the DRC.
However, 2026 could see a contraction of 1.5% in refined output due to tighter concentrate availability, particularly for primary electrorefining. Secondary refined production, which could grow by 6.4%, will partially offset that decline, as countries invest in recycling capacity to reduce dependency on mined copper.
ICSG also downgraded its copper usage growth forecasts, citing weaker global economic prospects exacerbated by trade policy uncertainty. Refined copper usage is expected to grow by 2.4% in 2025, down from a previous forecast of 2.7%, and slow further to 1.8% in 2026.
China, the world's largest copper consumer, is forecast to see demand growth fall from 2% this year to just 0.8% next year. Other major markets, including Europe, Japan, and the United States, are expected to remain subdued, leaving broader Asia as the main driver.
While structural trends such as energy transition technology and digital infrastructure support the long-term demand for copper, the ICSG believes that current trade disruptions dampen near-term consumption.
Copper inventories on global exchanges rose by 25% in the first quarter of 2025, primarily due to a surge in holdings on the Shanghai Futures Exchange, further reinforcing the oversupply trend.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44988722/freeport-mcmoran-exceeds-q1-copper-sales-estimates-expects-lower-copper-costs-amid-tariff-concerns" target="_blank" rel="noreferrer noopener">World's Largest Copper Producer Freeport Estimates Proposed Tariffs Could Raise US Cost Of Goods Purchased By 5%</a></li>
</ul>
Photo by TimBrew via Shutterstock

Asia

Large Cap

Emerging Markets

Commodities

Economics

COPX

CPER

IVPAF

JJCTF

JJMTF

JJNTF

Global Tensions To Drive Two-Year Copper Surplus, Study Group Warns

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li>Tvardi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

AMRN

AMWL

ARDX

ATPC

CAMP

CTSO

HCTI

MODV

PLRZ

RMTI

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press Releases

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Comments

Processa Pharmaceuticals

Processa Pharmaceuticals (PCSA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌